AnaptysBio Inc (ANAB)
21.17
+0.86
(+4.23%)
USD |
NASDAQ |
Nov 21, 16:00
21.18
+0.02
(+0.07%)
After-Hours: 20:00
AnaptysBio Enterprise Value: 214.06M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 214.06M |
| November 20, 2024 | 187.89M |
| November 19, 2024 | 177.54M |
| November 18, 2024 | 144.38M |
| November 15, 2024 | 148.03M |
| November 14, 2024 | 183.63M |
| November 13, 2024 | 201.28M |
| November 12, 2024 | 224.10M |
| November 11, 2024 | 251.49M |
| November 08, 2024 | 218.32M |
| November 07, 2024 | 223.80M |
| November 06, 2024 | 245.70M |
| November 05, 2024 | 174.81M |
| November 04, 2024 | 176.63M |
| November 01, 2024 | 229.58M |
| October 31, 2024 | 228.06M |
| October 30, 2024 | 244.79M |
| October 29, 2024 | 507.09M |
| October 28, 2024 | 497.65M |
| October 25, 2024 | 544.51M |
| October 24, 2024 | 550.30M |
| October 23, 2024 | 627.28M |
| October 22, 2024 | 639.45M |
| October 21, 2024 | 646.15M |
| October 18, 2024 | 634.28M |
| Date | Value |
|---|---|
| October 17, 2024 | 640.36M |
| October 16, 2024 | 625.45M |
| October 15, 2024 | 582.25M |
| October 14, 2024 | 626.98M |
| October 11, 2024 | 580.72M |
| October 10, 2024 | 543.60M |
| October 09, 2024 | 526.26M |
| October 08, 2024 | 554.25M |
| October 07, 2024 | 574.03M |
| October 04, 2024 | 603.85M |
| October 03, 2024 | 635.80M |
| October 02, 2024 | 634.89M |
| October 01, 2024 | 629.11M |
| September 30, 2024 | 589.24M |
| September 27, 2024 | 611.66M |
| September 26, 2024 | 630.99M |
| September 25, 2024 | 625.86M |
| September 24, 2024 | 702.56M |
| September 23, 2024 | 723.40M |
| September 20, 2024 | 811.28M |
| September 19, 2024 | 782.59M |
| September 18, 2024 | 753.60M |
| September 17, 2024 | 781.69M |
| September 16, 2024 | 818.53M |
| September 13, 2024 | 867.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-91.78M
Minimum
Nov 22 2019
867.15M
Maximum
Sep 13 2024
243.72M
Average
237.17M
Median
Jul 02 2020
Enterprise Value Benchmarks
| Eli Lilly and Co | 739.59B |
| Regeneron Pharmaceuticals Inc | 74.00B |
| Ligand Pharmaceuticals Inc | 1.983B |
| Agios Pharmaceuticals Inc | 2.163B |
| ADMA Biologics Inc | 5.050B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.85M |
| Revenue (Quarterly) | 30.02M |
| Total Expenses (Quarterly) | 52.77M |
| EPS Diluted (Quarterly) | -1.14 |
| Profit Margin (Quarterly) | -109.4% |
| Earnings Yield | -28.72% |
| Normalized Earnings Yield | -28.72 |